This work expands the application of cutaneous gene delivery of GLP1 for treating diseased states beyond obesity and diabetes and adds valuable supportive evidence of targeting GLP1 system as a novel treatment for AUD. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.